VIVSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
VivoSim Labs, INC.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.16+0.00 (+0.38%)
Close on Oct 19, 2026
- Market cap
- $825.22K
- P/E (TTM)
- –
- Dividend yield
- –
VivoSim Labs, INC. revenue by segment
By business segment
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Royalty [Member] | $131.00K | $119.00K | $109.00K | – | – | – | – | – | 100.0% | +10.1% |
| Product Revenue [Member] | $0 | $25.00K | – | – | – | – | – | – | 0.0% | -100.0% |
| Products and Services [Member] | – | – | – | – | $0 | $2.06M | $2.33M | $3.63M | – | – |
| Collaborations and Licenses [Member] | – | – | – | – | $0 | $89.00K | $171.00K | $422.00K | – | – |
| Grants [Member] | – | – | – | – | $0 | $52.00K | $587.00K | $554.00K | – | – |
By region
From the segment and revenue-disaggregation notes of VivoSim Labs's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.